Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma

Mantle cell lymphoma (MCL) is a heterogeneous disease with a poor prognosis. Despite years of research in MCL, relapse occurs in patients with current therapeutic options necessitating the development of novel therapeutic agents. Previous attempts to pharmacologically inhibit SRC-3 show effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Bijou, Imani, Liu, Yang, Lu, Dong, Chen, Jianwei, Sloan, Shelby, Alinari, Lapo, Lonard, David M., O’Malley, Bert W., Wang, Michael, Wang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029087/
https://www.ncbi.nlm.nih.gov/pubmed/36945511
http://dx.doi.org/10.21203/rs.3.rs-2653461/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029087/
https://www.ncbi.nlm.nih.gov/pubmed/36945511
http://dx.doi.org/10.21203/rs.3.rs-2653461/v1

Ejemplares similares